Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes--Biomarkers as a possible tool for early disease detection for rural screening.

OBJECTIVES This study aims to increase understanding of the connection between oxidative stress and inflammation in diabetes disease progression to provide a basis for investigating improved diagnostic possibilities, treatment and prevention of prediabetes. DESIGN AND METHODS Differences in the level of biochemical markers of oxidative stress (erythrocyte GSH/GSSG and urinary 8-isoprostane), inflammation (CRP, IL-6), endothelial dysfunction (plasma homocysteine, urinary 8-hydroxy-2-deoxy-guanosine) and coagulation/fibrinolysis (C5a, D-Dimer) were determined in prediabetes and control subjects. RESULTS While no difference was found in the 8-isoprostane levels between the two groups, the erythrocyte GSH/GSSG ratio was significantly reduced in the prediabetes group compared to control, indicating increased oxidative stress in the prediabetic state. Both urinary 8-OHdG and surprisingly also plasma homocysteine were significantly elevated in the prediabetes group, indicating endothelial dysfunction. The inflammation markers were slightly elevated in the prediabetic subjects and the same trend was found for the coagulation/fibrinolysis markers C5a and D-Dimer. These results were however not significant. CONCLUSIONS The small elevation of blood glucose levels in the prediabetic state may have a detectable influence on endothelial function as indicated by changes to 8-OHdG, indicating an increased DNA-damage and homocysteine release from endothelial cells. Increased oxidative stress as indicated by the reduced GSH/GSSG ratio is likely to be the link between the moderate hyperglycaemia in prediabetes and pathological changes in endothelial function, which in the long-term may promote atherogenesis and result in the development of cardiovascular disease. Early detection of prediabetes is essential to avoid diabetes development and the associated complications like cardiovascular disease. The GSH/GSSG ratio and biomarkers like urinary 8-OHdG and plasma homocysteine offer a possible tool for the assessment of prediabetes in prevention screenings.

[1]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[2]  E. S. Stovgaard,et al.  Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes. , 2011, Free radical biology & medicine.

[3]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .

[4]  R. Schnabel,et al.  Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. , 2005, Journal of the American College of Cardiology.

[5]  H. Jelinek,et al.  D‐dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications , 2007, Pathology.

[6]  Barbara Thorand,et al.  Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[7]  E. Sarandöl,et al.  Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. , 2006, Clinical biochemistry.

[8]  O. Ishihara,et al.  Isoprostanes, Prostaglandins and Tocopherols in Pre-eclampsia, Normal Pregnancy and Non-pregnancy , 2004, Free radical research.

[9]  E. Ferrannini,et al.  A comparative study of the in vitro antioxidant activity of statins. , 2003, International journal of cardiology.

[10]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[11]  LloydChambless,et al.  Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population , 2006 .

[12]  E. Topol,et al.  C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. , 2001, Cleveland Clinic journal of medicine.

[13]  Xun Jin,et al.  Oxidative stress and diabetes mellitus , 2011, Clinical chemistry and laboratory medicine.

[14]  S. Penckofer,et al.  Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. , 2002, The Journal of cardiovascular nursing.

[15]  G. Cerniglia,et al.  Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. , 1990, Analytical biochemistry.

[16]  S. Mahajan,et al.  Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs. , 2001, American journal of physiology. Cell physiology.

[17]  J. T. Lumeij,et al.  Avian Clinical Biochemistry , 1997 .

[18]  Wolfgang Rathmann,et al.  Prediabetes: a high-risk state for diabetes development , 2012, The Lancet.

[19]  Z. Bloomgarden Consequences of diabetes: cardiovascular disease. , 2004, Diabetes care.

[20]  Herbert F Jelinek,et al.  8-Hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in a rural prediabetes cohort , 2010, Redox report : communications in free radical research.

[21]  Guidelines Task Force Clinical Global guideline for type 2 diabetes , 2012 .

[22]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[23]  F. Paccaud,et al.  Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? , 2006, Swiss medical weekly.

[24]  I. Graham Homocysteine as a risk factor for cardiovascular disease. , 1991, Trends in cardiovascular medicine.

[25]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[26]  O. Griffith,et al.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. , 1980, Analytical biochemistry.

[27]  P. Monk,et al.  Complement component 5a (C5a). , 2009, The international journal of biochemistry & cell biology.

[28]  M. Yano,et al.  Urinary 8‐hydroxy‐2′‐deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure , 2011, European journal of heart failure.

[29]  W. T. Cade,et al.  Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting , 2008, Physical Therapy.

[30]  H. Jelinek,et al.  Atherothrombosis and oxidative stress: the connection and correlation in diabetes , 2009, Redox report : communications in free radical research.

[31]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[32]  H. İlkova,et al.  Effect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes mellitus. , 2002, Metabolism: clinical and experimental.

[33]  Edward T H Yeh,et al.  Coming of age of C-reactive protein: using inflammation markers in cardiology. , 2003, Circulation.

[34]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[35]  D. Aron,et al.  Sexual function in men with diabetes type 2: association with glycemic control. , 2000, The Journal of urology.

[36]  R. Tracy Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. , 2003, Chest.

[37]  D. Kereiakes,et al.  Endothelial dysfunction. , 2003, Circulation.

[38]  H. Jelinek,et al.  Oxidative DNA damage: antioxidant response in postprandial hyperglycaemia in type 2 diabetes mellitus , 2011 .

[39]  Rodica Pop-Busui,et al.  Cardiac Autonomic Neuropathy in Diabetes , 2010, Diabetes Care.

[40]  Sayeeda Rahman,et al.  Diabetes‐associated macrovasculopathy: pathophysiology and pathogenesis , 2007, Diabetes, obesity & metabolism.

[41]  G. King,et al.  The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO‐MCBN, the American Diabetes Association and the German Diabetes Society , 2001, Diabetes/metabolism research and reviews.

[42]  H. Jelinek,et al.  Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus , 2006, Redox report : communications in free radical research.

[43]  H. Jelinek,et al.  Oxidative DNA damage and obesity in type 2 diabetes mellitus. , 2011, European journal of endocrinology.

[44]  I. U. Haq,et al.  Statins for primary prevention: at what coronary risk is safety assured? , 2001, British journal of clinical pharmacology.

[45]  M. Katz,et al.  Reassessing benefits and risks of statins. , 2012, The New England journal of medicine.